Kailera Therapeutics (KLRA) stock
Follow KLRA's trial news. Pro members can get an alert when Kailera Therapeutics files news, and see its trials, share raises, and its CEO's filings.
KLRA's Quality Score fell 1 point on Fri, Oct 2, to -2.
What's next for KLRA, and how long its cash lasts
From Kailera Therapeutics’s SEC filings and ClinicalTrials.gov: the company’s own words, the registry’s dates, and arithmetic, not a forecast. Companies often miss their own dates.
Next step the company has named
Cash runway
$1.2B in cash
Dilution on the horizon
No shelf registration of its own or at-the-market program on file in the last three years.
Insiders
Director Adam Koppel bought 1,562,500 shares on Apr 20. 1 more insider trade this year.
FDA dates in the next 60 days
Decision dates and advisory committee meetings the companies have announced in their own filings, soonest first and small companies first.
- In 28 daysINOInovio Pharmaceuticals
INOINO-3107
- In 39 daysNRXPNRX Pharmaceuticals
NRXPDrug not named
- In 51 daysCAPRCapricor Therapeutics
CAPRDrug not named
Why it's down
Down 50% in 3 months, 30% under its 50-day average.
Down more than its industry: the 299 other stocks in it fell a median 14% over the same 3 months.
−2Volatility moves 9.7% a day with no profit or positive free cash flow over four quarters on file
What's next
Tue Oct 13: IPO lockup endsAt the open. The 180-day lockup ends.
Reports Wed Nov 4, after the close
After its last 2 reports it closed -0.9% on average, higher 1 of 2 times.
1 more date ahead for Pro members: the IPO anniversary
What would turn KLRA's score around: 3 things, for Pro members
Here is what Pro members see.
Every stock has a live page like this, KLRA included: the price in real time, the full chart, all 14 checks, and every line of its score.
- Prices refresh every 2.5 seconds during market hours.
- Optional alerts by push, email, or the bell.
- Add it to your Home Screen and it opens like an app.
Nothing is firing on KLRA right now
One per group is shown here.
Also on the chart
- RSI 1427.9
- MACD (12, 26, 9)Below signal
- 50-day average$15.69
- ADX 1442.9
- Resistance$18.78
- Bollinger Bands (20, 2)Inside
- Volume1.0x
How KLRA ranks in Biotech
KLRA is #194 of 300 by Quality Score. The top three are shown with their scores, and more by name.
KNSA7/1418
EXEL7/1417
AMRX6/1417
IRONOpen for its score
JAZZOpen for its score
KODOpen for its score
KLRA0/14-2
When does KLRA report earnings, and what happens after?
Reports Wed Nov 4, after the close (in 33 days). The company has set the date.
| Reported | When | Gap | Reaction | 5 sessions |
|---|---|---|---|---|
| Aug 12, 2026After close | After close | +0.2% | -3.3% | -1.4% |
| May 26, 2026After close | After close | +1.8% | +1.6% | +4.7% |
About Kailera Therapeutics
Kailera Therapeutics Inc is a clinical-stage biotechnology company. The company focuses on developing a diversified pipeline to provide options for people living with obesity. The company is progressing four clinical-stage product candidates, leveraging multiple GLP-1 based mechanisms of action and routes of administration. The company's obesity-first approach seeks to advance product candidates with the potential to maximize weight loss and address critical needs in the current therapeutic landscape.
Every line of the score, on every stock.
- Real-time prices, no delay
- Every line of KLRA's score, with the points and the reason
- All 14 checks on KLRA and on all 3,243 stocks
- Every stock ranked, with the chart
- Every filing, and optional alerts on KLRA
Straight Answers.
Are the prices delayed?
Only on the public pages, which run at least 15 minutes behind. Pro members, trial included, see real-time prices: the scanner refreshes every 15 seconds, and your watchlist every few seconds, pre-market and after hours included.
Where does the data come from?
Daily bars, quotes, reference data, headlines, and short interest come from Massive, formerly Polygon, a licensed market data vendor. The age of the quotes is shown at the top of every page. Insider trades, notable holders and profits come straight from the SEC. That means Form 4 filings, 13F filings and XBRL financial data on EDGAR. Government filings come from the public STOCK Act and Office of Government Ethics disclosures. The market-wide headlines on the market line also come from the public headline feeds CNBC, MarketWatch and Yahoo Finance publish, shown as the headline, the source and a link to the article. Splits, dividends, and the financial statements on each ticker page come from the vendor's reference data. The 8-K filings on EDGAR are read for the items that move a price. Five years of history is loaded for every stock. So the 200-day and 52-week checks rest on real history. Options flow is not part of the product.
Do I need an account?
Not for the first 24 hours. Tap any green button and you're in, with no email and no password. To keep going, create a free account with Google, Apple, or your email. There is no password to make up.
Is this investment advice?
No. It is a screening tool that scores stocks on the chart, the company's own results, and the news and filings. It does not know your situation and it is not a recommendation to buy or sell anything. Please do your own research.